Engineered regulatory t cell
An engineered, intracellular domain technology that can be used in animal cells, vertebrate cells, genetically modified cells, etc., and can solve problems related to high IL-2 dependence
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0454] Example 1 - Production of anti-HLA.A2 IL2R CAR-Treg
[0455] CD4 + CD25 高 CD127 低 cells and activated with anti-CD3 / CD28 beads. Three days after activation, use HLA.A2-CAR (such as figure 2 indicated) and lentiviral transduction of GFP reporter gene Treg. After polyclonal activation, the cellular expansion of total Tregs showed no significant difference between non-transduced or transduced Tregs ( image 3 ).
Embodiment 2
[0456] Example 2 - Anti-HLA.A2 Quantification of transduction efficiency of IL2R constructs over time
[0457] GFP expression on untransduced Tregs and Tregs transduced with CAR constructs was analyzed at different time points after cell activation.
[0458] The frequency of GFP+ cells was analyzed to assess the transduction efficiency and expression persistence of the different constructs during Treg expansion. Tregs containing dCAR, CD28z, Construct 1, Construct 2, and Construct 3 showed similar expression frequencies after transduction. The percentage of GFP+ cells in the whole Treg was maintained during polyclonal cell expansion ( Figure 4 ).
Embodiment 3
[0459] Example 3 - Quantification of Cell Surface Expression of Anti-HLA.A2 IL2R CAR Constructs on Transduced Tregs
[0460] Membrane expression of the CAR constructs on non-transduced and transduced Tregs was analyzed by PE-conjugated HLA-A*0201 / CINGVCWTV dextroform (Immudex, Copenhagen, Denmark). The frequency of Treg expressing CAR protein on the cell surface among all constructs (HLA-A2 dextromorph + )resemblance( Figure 5 ).
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


